Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Inclusion Criteria: * 18 to 75 years of age * Written informed consent including authorization to release health information * Focal upper limb spasticity (ULS) after a stroke (as defined by WHO criteria) or traumatic brain injury (TBI), last stroke or TBI \> 24 weeks prior to Screening * ULS with the primary aggregate posture * Moderate to severe ULS with a MAS score ≥ 2 at the elbow, wrist, and finger flexors * Moderate to severe functional disability (Disability Assessment Score \[DAS\] score ≥2) on the principal target of treatment * Has sufficient cognitive and communication ability to be able to give informed consent Exclusion Criteria: * Upper limb spasticity attributable to an etiology other than stroke or TBI. * Bilateral upper limb paresis or quadriplegia. * Initiated in physiotherapy of the upper extremities ≤ 30 days prior to Screening or planned to start physiotherapy of the upper extremities during the course of the study. * Previous or planned treatment of the spastic upper limb with phenol, alcohol injection, or surgery * Profound muscular atrophy or fixed contracture leading to marked limitation on range of motion * Prior treatment with intrathecal baclofen * Any neuromuscular neurologic conditions (amyotrophic lateral sclerosis, Lambert- Eaton, myasthenia gravis)